DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoarthritis

Intervention: Paracetamol 665 mg (Drug); Paracetamol 500 mg (Drug)

Phase: N/A

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Summary

The aim of this observational study is to compare the use of an extended release paracetamol formulation with standard paracetamol in a cohort of Australian concessional patients with osteoarthritis (OA), to assess differences in prescribing patterns and patient compliance.

Clinical Details

Official title: Panadol Osteo PBS Claims Cohort Study

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome:

Relative number of prescriptions of an extended release paracetamol formulation and a standard release paracetamol formulation.

Relative treatment compliance with an extended release paracetamol formulation and a standard release paracetamol formulation

Detailed description: This retrospective analysis of physician prescribing data (long-term concessional cohort from the Medicare Australia PBS claims dataset for the time period 2008-2011 (4 years) will compare the use of extended release paracetamol (Panadol Osteo) with standard paracetamol 500mg in a cohort of Australian concessional patients with OA, to assess differences in prescribing patterns and patient compliance.

Eligibility

Minimum age: 50 Years. Maximum age: 85 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Participants prescribed with a paracetamol product and categorized as a concessional

patient

- Participants with new episodes of OA (no history of OA paracetamol in previous 12

months) or suffering from chronic OA (history of OA paracetamol in the previous 12 months) Exclusion Criteria:

- Participants with Rheumatoid arthritis or other auto-immune inflammatory conditions

- Participants receiving the following anti-rheumatoid therapies: Immunimodulators such

as methotrexate, leflunamide and TNF blockers

- Participants receiving treatment for cancer pain

Locations and Contacts

Additional Information

Starting date: January 2013
Last updated: December 11, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017